CancerIQ, a platform powering early cancer detection and prevention across broad patient populations, closed a $14 million Series B financing round co-led by Merck Global Health Innovation Fund and Amgen Ventures. McKesson Ventures, OSF Ventures (the investment arm of OSF HealthCare, a current CancerIQ customer), as well as CancerIQ’s Series A lead investor, HealthX Ventures, also participated in the round. Read more.
CancerIQ Raises $14M Series B Funding
